Clinical Trials Logo
  1. Home
  2. Neoplasms, Prostate
  3. NCT00056407

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — REDUCE  

Neoplasms, Prostate Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

Clinical Trial Summary

This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00056407
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 3
Start date March 2003
Completion date May 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT02652000 - Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy N/A
Completed NCT00558363 - ARTS - AVODART After Radical Therapy For Prostate Cancer Study Phase 2
Completed NCT02153918 - Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy Phase 2
Completed NCT01371513 - Korean Practice Patterns for Screening PCA(Prostate Cancer) N/A
Completed NCT00470834 - Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Phase 4
Completed NCT00148928 - Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA Phase 1
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2
Completed NCT00363311 - Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Phase 4
Completed NCT01337258 - Economic Analyses of the REDUCE Trial N/A
Terminated NCT02349139 - Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer Phase 1
Active, not recruiting NCT04249947 - P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) Phase 1
Completed NCT00883909 - ARI103094-Follow-Up Study for REDUCE Study Subjects N/A